In experiments involving lung cancer gene mice treated with low-dose Apatinib in combination with PD-L1 inhibitors, it was observed that the concurrent administration of low-dose Apatinib and anti-PD-L1 significantly delayed tumor growth. Here, CD274 is linked to lung cancer.